Davita Inc vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while T-Rex 2X Long MSTR Daily Target ETF trades at $39.78 (market cap $809.00M). The key difference: Davita Inc is far larger — about 14× T-Rex 2X Long MSTR Daily Target ETF's market cap, and Davita Inc is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and T-Rex 2X Long MSTR Daily Target ETF for 18 Days on average.
| DVA | MSTU | |
|---|---|---|
Market Cap | $11.29B | $809.00M |
Volume | 582,204 | 4,577,465 |
Sector | Health | Leveraged / Inverse |
52-Week High | $240.96 | $451.00 |
52-Week Low | $103.87 | $14.60 |
Typical Hold Time | 113 Days | 18 Days |
Enterprise Value | $24.01B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
MSTU is experiencing significant downward pressure with the stock declining 13.68% to $39.45 amid bearish technical signals. The reverse stock split effective August 24, 2026, and upcoming dividend payment suggest corporate restructuring efforts. Technical indicators show mixed signals with moving averages bearish but oscillators neutral, while support levels cluster around $36-38.
The outlook remains challenging with technical weakness and limited fundamental visibility. Investment opportunity exists for contrarian investors betting on stabilization, though risks include continued volatility from leveraged ETF mechanics and dependence on underlying stock performance. The absence of key financial ratios warrants caution for fundamental investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →